BIOMAT Database Logo BIOMAT Database Logo

Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. 1990

A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Department of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston 77030.

Two Pediatric Intergroup Ewing's Sarcoma studies of patients with metastatic disease (IESS-MD) have used multimodal therapy consisting of intensive combination chemotherapy and radiation therapy (XRT) to areas of gross disease detected at the time of diagnosis. In IESS-MD-I, conducted from 1975 to 1977, 53 eligible patients were entered and received the chemotherapeutic agents vincristine, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), cyclophosphamide, and dactinomycin with concomitant XRT (VACA + XRT). In IESS-MD-II, conducted from 1980 to 1983, 69 eligible patients were entered and received 5-fluorouracil (5FU) in addition to the chemotherapeutic agents of IESS-MD-I; initial intensive chemotherapy was given and XRT was delayed until week 10 (VACA + 5FU, delayed XRT). The best response rate (complete and partial remissions combined) was 73% in IESS-MD-I and 70% in IESS-MD-II, so there was no statistical evidence of a difference in response rates (P = 0.62). The length of best response also was similar between studies (P = 0.79), with approximately 30% of the patients on both studies remaining in remission at 3 years. The percentage of patients surviving 5 years or more was 30 on the first study and 28 on the second study (P = 0.49). The major sites of relapse after a response were lung and bone, each occurring with nearly equal frequency. The age of the patient was related to both best response rate and survival: patients 10 years of age or younger had substantially higher response and survival rates than patients 11 years of age or older. The favorable prognosis for younger patients might be explained by a more favorable distribution of primary sites at diagnosis; 39% of patients 10 years of age or younger had rib primary sites, compared with only 16% for patients older than 10 years of age (P = 0.05). The frequency of life-threatening toxicity was substantially higher in IESS-MD-I (30%) than in IESS-MD-II (9%), but the frequency of fatal toxicity was similar (6% to 7%). Fatal complications included Adriamycin-induced cardiomyopathy, Pneumocystis carinii pneumonia, unspecified pneumonitis, and sepsis. The most common toxicity and complications were leukopenia and infections.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005260 Female Females

Related Publications

A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Multimodal therapy in metastatic Ewing's sarcoma: an Intergroup Study.
April 1981, National Cancer Institute monograph,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
[EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study)-- preliminary results].
January 1999, Klinische Padiatrie,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies.
October 1993, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Primary Ewing's sarcoma of the ribs. A report from the intergroup Ewing's sarcoma study.
March 1983, Cancer,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
The role of radiation therapy in the management of non-metastatic Ewing's sarcoma of bone. Report of the Intergroup Ewing's Sarcoma Study.
February 1981, International journal of radiation oncology, biology, physics,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study.
September 1983, Human pathology,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients.
September 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Radiotherapy and combination chemotherapy in advanced Ewing's Sarcoma-Intergroup study.
April 1981, Cancer,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Ewing's sarcoma metastatic to placenta.
January 1982, Placenta,
A Cangir, and T J Vietti, and E A Gehan, and E O Burgert, and P Thomas, and M Tefft, and M E Nesbit, and J Kissane, and D Pritchard
Intramyofiber skeletal muscle invasion in Ewing's sarcoma of bone: clinicopathologic observations from the intergroup Ewing's sarcoma study.
January 1982, The American journal of pediatric hematology/oncology,
Copied contents to your clipboard!